US2016303074A1PendingUtilityA1

Methods to mitigate injury from radiation exposure by administering cxcr4 antagonist during decisive treatment window

45
Assignee: FORD HENRY HEALTH SYSTEMPriority: Oct 28, 2009Filed: Jun 20, 2016Published: Oct 20, 2016
Est. expiryOct 28, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Jae-Ho KimStephen L. BrownAndrew Kolozsvary
A61P 7/00A61P 43/00A61P 39/00A61K 38/193A61K 31/4402A61K 38/10A61K 31/4709A61K 38/12A61K 31/506A61K 31/395A61K 39/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal at least once within a decisive treatment window wherein the window opens 48 hours after exposure.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of mitigating radiation induced injury to a mammal that has been exposed to an external source of radiation, comprising the step of administering a therapeutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal at least once within a decisive treatment window wherein the window opens 1 day after exposure. 
     
     
         2 . The method of  claim 1  wherein the decisive treatment window closes on the 3′ day after exposure. 
     
     
         3 . A method of mitigating radiation induced injury to a mammal that has been exposed to an external source of radiation, comprising the step of administering a therapeutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal at least once within a decisive treatment window wherein the window opens 2 days after exposure. 
     
     
         4 . The method of  claim 3  wherein the decisive treatment window closes on the 3′ day after exposure. 
     
     
         5 . A method of mitigating radiation induced injury to a mammal that has been exposed to an external source of radiation, comprising the step of administering a therapeutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal at least once within a decisive treatment window wherein the window opens 3 days after exposure. 
     
     
         6 . The method of  claim 1  wherein the mammal has been exposed to a lethal dose of external radiation. 
     
     
         7 . The method of  claim 2  wherein the mammal has been exposed to a lethal dose of external radiation. 
     
     
         8 . The method of  claim 3  wherein the mammal has been exposed to a lethal dose of external radiation. 
     
     
         9 . The method of  claim 4  wherein the mammal has been exposed to a lethal dose of external radiation. 
     
     
         10 . The method of  claim 5  wherein the mammal has been exposed to a lethal dose of external radiation. 
     
     
         11 . The method of  claim 4  wherein the mammal has been exposed to an acute lethal dose of external radiation. 
     
     
         12 . The method of  claim 6  wherein the method has an increased survival relative to the survival for an identical dosing regimen of the composition occurring within a treatment window opening at time of exposure and closing on the 1 st  day after exposure. 
     
     
         13 . The method of  claim 7  wherein the method has an increased survival relative to the survival for an identical dosing regimen of the composition occurring within a treatment window opening at time of exposure and closing on the 1 st  day after exposure. 
     
     
         14 . The method of  claim 8  wherein the method has an increased survival relative to the survival for an identical dosing regimen of the composition occurring within a treatment window opening at time of exposure and closing on the 1 st  day after exposure. 
     
     
         15 . The method of  claim 9  wherein the method has an increased survival relative to the survival for an identical dosing regimen of the composition occurring within a treatment window opening at time of exposure and closing on the 1 st  day after exposure. 
     
     
         16 . The method of  claim 10  wherein the method has an increased survival relative to the survival for an identical dosing regimen of the composition occurring within a treatment window opening at time of exposure and closing on the 1 st  day after exposure. 
     
     
         17 . The method of  claim 1  wherein the mammal is a human. 
     
     
         18 . The method of  claim 9  wherein the CXCR4 antagonist is plerixafor. 
     
     
         19 . The method of  claim 17  wherein the CXCR4 antagonist is Mozobil. 
     
     
         20 . The method of  claim 17  wherein the CXCR4 antagonist is AMD-3100. 
     
     
         21 . The method of  claim 1  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor. 
     
     
         22 . The method of  claim 2  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor. 
     
     
         23 . The method of  claim 3  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor. 
     
     
         24 . The method of  claim 4  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor. 
     
     
         25 . The method of  claim 5  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor. 
     
     
         26 . The method of  claim 11  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor. 
     
     
         27 . The method of  claim 16  wherein the CXCR4 antagonist is co-administered with a granulocyte colony-stimulating factor.

Join the waitlist — get patent alerts

Track US2016303074A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.